Related by context. All words. (Click for frequent words.) 79 metastasis 76 metastatic disease 76 distant metastases 75 tumors 75 metastatic lesions 73 metastatic cancer 72 metastatic tumors 72 tumor recurrence 72 lymph node metastases 71 metastatic 71 lung tumors 71 liver metastases 71 carcinoma 70 micrometastases 70 carcinomas 70 distant metastasis 69 malignancies 69 GISTs 69 lymph node metastasis 69 lesions 68 tumor 68 adenocarcinomas 68 malignancy 68 neuroendocrine tumors 67 renal tumors 67 lung metastases 67 neoplasms 67 pancreatic adenocarcinoma 67 adenomas 66 adenoma 66 brain metastases 66 lymph nodes 66 advanced adenomas 66 pancreatic cancers 66 liver metastasis 66 ovarian tumors 66 pulmonary metastases 65 epithelial tumors 65 lobular carcinoma 65 bladder cancers 65 neoadjuvant therapy 65 breast tumors 65 breast carcinoma 65 metastatic prostate cancer 65 PCa 65 tumor cells 65 lymph node involvement 65 malignant lesions 65 colorectal tumors 65 bone metastasis 64 prostate cancers 64 renal cell carcinomas 64 lymph node 64 metastatic tumor 64 precursor lesions 64 gastric cancer 64 malignant tumors 64 ductal 64 lung nodules 64 glioblastomas 64 neoplasia 64 uveal melanoma 64 neoplastic cells 64 tumoral 63 melanomas 63 contralateral breast 63 hepatocellular carcinoma 63 cystectomy 63 mucinous 63 metastatic cancers 63 axillary lymph nodes 63 metachronous 63 micrometastasis 63 breast carcinomas 63 neoadjuvant chemotherapy 63 endometrial cancers 63 meningiomas 63 hepatocellular carcinoma HCC 63 cytoreductive surgery 63 carcinoid 63 gastric cancers 63 histologically 63 neoplasm 63 breast cancers 63 locoregional 63 bone metastases 63 cancers 63 hamartomas 63 colorectal carcinoma 63 sarcomas 62 adenomatous polyps 62 resection 62 locoregional recurrence 62 biochemical recurrence 62 nodal metastases 62 Tumours 62 urothelial carcinoma 62 fibrosis 62 ovarian carcinoma 62 metastatic RCC 62 lymphatic tissue 62 node metastases 62 anaplastic 62 intestinal metaplasia 62 EUS FNA 62 nodal metastasis 62 malignant growths 62 paragangliomas 62 sarcomatoid 62 retroperitoneal 62 prostate cancer CaP 62 chemoradiation 62 cell carcinomas 62 adjuvant therapy 62 GIST tumors 62 radical nephrectomy 62 prostate adenocarcinoma 61 pancreatic tumors 61 benign lesions 61 renal cell carcinoma 61 recurrences 61 sentinel nodes 61 resected 61 leukemic cells 61 Tumors 61 sentinel node 61 NSCLC 61 premalignant 61 lesion 61 osteosarcomas 61 melanoma tumors 61 activating mutations 61 Metastatic 61 sentinel lymph nodes 61 resectable 61 neoplastic lesions 61 axillary dissection 61 ascites 61 pelvic lymph nodes 61 squamous cell carcinoma 61 carcinoid tumor 61 neuroblastomas 61 HNSCC 61 tumor resection 61 pCR 61 colorectal cancers 61 papillary 61 basal cell carcinomas 61 occult metastases 61 ovarian cancers 61 breast lesions 61 Carcinoma 61 esophageal carcinoma 61 atypical hyperplasia 61 mesotheliomas 61 solid tumors 61 adenocarcinoma 61 gastric adenocarcinoma 61 carcinoid tumors 61 proximal colon 61 prostate tumor 61 lung metastasis 60 EGFR mutations 60 pituitary adenomas 60 pleomorphic 60 colorectal cancer CRC 60 adenomatous 60 prostate carcinoma 60 preoperative chemotherapy 60 soft tissue sarcomas 60 axillary nodes 60 extracapsular extension 60 pT2 60 peritoneal carcinomatosis 60 hyperplastic 60 polyps 60 metastatic melanomas 60 situ LCIS 60 pheochromocytoma 60 PSADT 60 HER2 positive tumors 60 HER2 positive 60 esophagogastric junction 60 p# mutations 60 leiomyomas 60 chemoradiotherapy 60 EBRT 60 papillary RCC 60 seminomas 60 benign polyps 60 tumor shrinkage 60 ADPKD 60 lymphovascular invasion 60 invasive carcinoma 60 schwannomas 60 mediastinal 60 CaP 60 prognostic indicator 60 lymphadenopathy 60 skeletal metastases 60 squamous cell carcinomas 60 histologic 59 myeloma cells 59 ALND 59 luminal 59 thymoma 59 cervical lymph nodes 59 serous ovarian cancer 59 differentiated thyroid 59 nodules 59 TIMP 59 thrombi 59 WT1 59 malignant cells 59 gastric carcinoma 59 operable breast cancer 59 colorectal adenocarcinoma 59 hyperplasia 59 axillary node dissection 59 pancreatic carcinoma 59 pre cancerous polyps 59 cystic lesions 59 MGUS 59 pT3 59 pancreatic tumor 59 neoplastic 59 calculi 59 biochemical relapse 59 medulloblastoma 59 varices 59 leiomyosarcoma 59 Papillary 59 atherosclerotic lesions 59 lymphoid 59 follicular lymphoma 59 cancerous cells 59 adjuvant radiation 59 colon tumors 59 pathologic 59 nephrectomy 59 medullary thyroid cancer 59 Recurrences 59 cytoreduction 59 cancerous lesions 59 germline mutations 59 prostate breast 59 BRCA mutations 59 biopsies 59 IGF 1R 59 cancerous tumors 59 thyroid carcinoma 59 premalignant lesions 59 PNET 59 fibroadenomas 59 Metastases 59 squamous cell carcinoma SCC 59 pulmonary nodules 59 unresectable 59 hepatic metastases 59 lymphomas 59 sentinel lymph node biopsy 59 hypermethylation 59 cell carcinoma 59 transitional cell carcinoma 59 seminal vesicle invasion 59 pulmonary metastasis 59 lymph node removal 59 basal cell carcinoma BCC 59 parenchyma 59 nasopharyngeal carcinoma 59 malignant pleural mesothelioma 58 stage IIIB 58 biliary tract cancer 58 medically inoperable 58 tumor progression 58 tumor metastases 58 breast cancer recurrence 58 mediastinum 58 testis 58 glioblastoma 58 malignant transformation 58 epithelial cancers 58 MALT lymphoma 58 underwent resection 58 contralateral breast cancer 58 HbF 58 stroma 58 advanced adenoma 58 osteochondromas 58 nonmetastatic 58 prostate tissue 58 FDG PET 58 astrocytoma 58 breast cancer metastasis 58 lymphadenectomy 58 endometrial carcinoma 58 NMIBC 58 colorectal neoplasms 58 lung cancers 58 papillary renal cell carcinoma 58 thyroid nodules 58 thyroglobulin 58 thyroid nodule 58 TACE 58 completely resected 58 BRAF mutations 58 disease progression 58 leiomyoma 58 androgen deprivation 58 cholangiocarcinoma 58 adjuvant therapies 58 lung carcinomas 58 GBM tumors 58 bowel cancers 58 chemoembolization 58 squamous 58 axillary lymph node dissection 58 esophageal cancers 58 synovial sarcoma 58 p# mutation 58 B7 H3 58 renal carcinoma 58 malignant prostate 58 metastatic melanoma 58 malignant lymphoma 58 SLNB 58 nonmelanoma skin cancers 58 castration resistant prostate cancer 58 colorectal liver metastases 58 grade gliomas 58 pre malignant lesions 58 metastatic lesion 58 endometrial 58 supratentorial 58 ALK mutations 58 adjuvant radiotherapy 58 dysplastic 58 lung adenocarcinomas 58 KIT mutations 58 haematopoietic 58 pneumonectomy 58 lipomas 58 resections 57 neoadjuvant 57 stage IIIA 57 SUVmax 57 peritoneal cancer 57 BRAF mutation 57 recurrent NSCLC 57 prognostic factor 57 infarcts 57 angiosarcoma 57 lymphoid tissue 57 rectal cancers 57 underarm lymph nodes 57 colorectal polyps 57 prognostic factors 57 CMV disease 57 hepatic metastasis 57 CIN2 57 recurrent prostate cancer 57 hepatocellular carcinomas 57 amyloid deposition 57 neoplasias 57 ductal carcinomas 57 cutaneous melanoma 57 axillary 57 prostate cancer CRPC 57 ductal cancer 57 EGFR mutation 57 hyperplastic polyps 57 bladder tumors 57 glioma cells 57 chondrosarcoma 57 histopathologic examination 57 teratoma 57 metastatic bladder 57 ependymoma 57 mRNA expression 57 Circulating tumor cells 57 CLL cells 57 atypia 57 EGFr 57 colorectal cancer 57 cisplatin 57 dysplasia 57 pleural mesothelioma 57 transurethral resection 57 intraductal 57 DLBCL 57 bronchogenic carcinoma 57 lymph node dissection 57 noncancerous cells 57 curative resection 57 radical prostatectomy RP 57 surgical resection 57 K ras mutations 57 oropharyngeal cancer 57 amyloid deposits 57 lobular carcinomas 57 radical prostatectomy 57 liver resection 57 malignant neoplasm 57 submucosa 57 myoepithelial cells 57 esophageal tumors 57 superficial bladder cancer 57 cyclin D1 57 sentinel lymph node 57 sentinel node biopsy 57 rectal carcinoma 57 epithelioid 57 fallopian tube carcinoma 57 infarct 57 hydronephrosis 57 infarct size 57 pheochromocytomas 57 gastrointestinal stromal tumors 57 squamous cell cancers 57 renal pelvis 57 orthotopic 57 c MYC 57 melanoma 57 paraganglioma 57 prostatic 57 colon cancers 57 ALCL 57 autoantibodies 57 carcinoids 57 thromboembolic events 57 malignant nodules 57 malignant pancreatic 57 chromosomal aberrations 57 medulloblastomas 57 submandibular gland 57 Barrett esophagus 57 lobular cancer 57 Radical prostatectomy 57 reimplantation 57 hepatocellular cancer 57 ependymomas 57 lymphocytosis 56 astrocytomas 56 Sarcomas 56 hematuria 56 myeloproliferative diseases 56 seminal vesicles 56 metastatic lung cancer 56 EGFR 56 malignant neoplasms 56 fallopian tube cancers 56 imatinib therapy 56 KRAS mutations 56 N Myc 56 5FU 56 gastrointestinal cancers 56 cyclin E 56 cervical carcinoma 56 EGF receptors 56 lobular breast cancer 56 calcifications 56 epithelial 56 HER2 positive breast cancer 56 BRCA deficient 56 Glioma 56 tumor metastasis 56 gadolinium enhanced 56 chemoresistance 56 epithelial ovarian 56 HER2 positive cancers 56 metastatic renal cell carcinoma 56 urothelial cancer 56 basal cells 56 mammary cancers 56 squamous cell 56 intestinal polyps 56 chromosomal abnormalities 56 endoscopic resection 56 prostate cancer PCa 56 MYCN amplification 56 proto oncogene 56 metaplasia 56 histological subtype 56 core needle biopsy 56 extrahepatic 56 ductal breast cancer 56 epithelial tissues 56 uterine cancers 56 metastasise 56 hormone receptor negative 56 HGPIN 56 precancerous lesions 56 grade cervical intraepithelial 56 liver fibrosis 56 Polyps 56 basal cell carcinoma 56 morphologic 56 metastatic malignant melanoma 56 hormone receptor positive 56 Malignant tumors 56 cancerous polyps 56 Gliomas 56 metastatic breast cancer 56 esophagectomy 56 sarcoma 56 radioiodine therapy 56 unresectable tumors 56 neurofibromas 56 perioperative complications 56 E#F# 56 BCR ABL mutations 56 VEGF receptor 56 extracranial 56 peritumoral 56 kidney cysts 56 ischemic lesions 56 pelvic lymphadenectomy 56 debulking surgery 56 hamartoma 56 KRAS mutation 56 axillary node 56 cell lymphomas 56 EGF receptor 56 tumor subtypes 56 TNFa 56 Lymph node 56 chemoresistant 56 hypopharynx 56 catheter angiography 56 autoantibody 56 neuroblastoma cells 56 pericardial effusion 56 cervical lymph node 56 prognostic marker 56 gastric atrophy 56 gliomas 56 extranodal 56 HER2 expression 56 colorectal tumor 56 keloid 56 NF1 56 heavily pretreated 56 mediastinal lymph nodes 56 atherosclerotic disease 56 testicular cancers 56 infiltrative 56 reintervention 56 EGFRvIII 56 SCCHN 56 malignant tissue 56 breast cancer subtypes 56 neuroendocrine cancers 56 benign tumors 56 mediastinoscopy 56 bone resorption 56 seminoma 56 axilla 56 radiochemotherapy 56 vestibular schwannomas 56 osteoid 56 mammary tumors 56 IGF IR 56 inflammatory lesions 56 basal cell cancer 56 overexpression 56 EGFR inhibitors 56 TRUS biopsy 56 cancerous growths 56 radiotherapy RT 56 lymphoid cells 56 adrenalectomy 55 endosonography 55 Cholangiocarcinoma 55 xenograft tumors 55 IV NSCLC 55 E cadherin 55 castrate resistant 55 mutant p# 55 glioblastoma tumors 55 cerebral vasospasm 55 microvascular complications 55 oncoprotein 55 adjuvant chemotherapy 55 TGF β 55 clinically localized prostate 55 gastroesophageal junction 55 cysts 55 HER2 receptor 55 acinar 55 echogenicity 55 papillary carcinoma 55 peritoneal 55 situ DCIS 55 parathyroid 55 metastatic neuroendocrine tumors 55 Glioblastoma 55 iNOS 55 HSCT 55 cisplatin resistant 55 intravesical therapy 55 IGFBP 55 metastatic lymph nodes 55 anti apoptotic proteins 55 neovascularization 55 metastatic basal cell 55 curable cancers 55 synovial 55 metastatic prostate 55 trophoblasts 55 partial nephrectomy 55 tunica vaginalis 55 FDG uptake 55 osteochondroma 55 microbleeds 55 renal parenchyma 55 R0 resection 55 Aβ 55 precancer 55 CTGF 55 transgene expression 55 metastatic colorectal 55 Immunohistochemical analysis 55 neuroendocrine carcinoma 55 stromal 55 precancerous lesion 55 myocardial ischemia 55 TET2 55 splenic 55 prostate tumors 55 recanalization 55 nodular 55 intrahepatic 55 cervical lesions 55 lymphatic vessels 55 NAFLD 55 Lymph nodes 55 APOL1 55 leukemic stem cells 55 MAPK pathway 55 breast endometrial 55 nephron sparing surgery 55 pre cancerous lesions 55 benign growths 55 echogenic 55 esophageal squamous cell carcinoma 55 immunocompetent 55 ventricular dysfunction 55 recurrent ovarian 55 HER2 amplification 55 endostatin 55 nephropathy 55 TNFα 55 locoregional disease 55 graft dysfunction 55 benign neoplasms 55 metastatic pancreatic 55 gastrectomy 55 basal cell nevus syndrome 55 postoperative chemotherapy 55 HBeAg negative 55 chemo resistant 55 pre cancerous cells 55 survivin 55 pDCs 55 T2DM 55 gastrointestinal stromal tumor 55 Tumor shrinkage 55 clinicopathological features 55 castration resistant 55 vascularization 55 tumor regression 55 epithelia 55 wedge resection 55 EpCAM 55 prognostic markers 55 chemotherapeutic agents 55 paroxysmal AF 55 desmoplastic 55 sonographic 55 BCG refractory 55 papillary thyroid cancer 55 F FDG PET 55 hepatoma 55 hypoperfusion 55 cetuximab 55 axillary lymph node 55 epithelial cell 55 EGFR gene 55 cystic 55 situ CIS 55 recurrent glioblastoma multiforme 55 nodal dissection 55 cancerous tissue 55 Squamous Cell Carcinoma 55 endoleaks 55 hypermethylated 55 node dissection 55 fibrotic disease 55 lobectomy 55 osteoblastic 55 immunohistochemical staining 55 Hurthle cell 55 liposarcoma 55 CMV infection 55 basal cell cancers 55 polypoid 55 multidrug resistance 55 Benign tumors 55 lung fibrosis 55 chromosomal mutations 55 histologic subtype 55 explants 55 parenchymal 55 hepatectomy 55 tumorigenesis 55 pancreatic lung 55 Histological examination 55 pilocytic astrocytomas 55 sonographically 55 lobular 55 RALP 55 postoperative morbidity 55 proteoglycan 55 metastatic GIST 55 sCJD 55 lymphangiogenesis 55 heterotopic ossification 55 invasive ductal 55 ipsilateral 55 Metastasis 55 BRCA2 mutation carriers 55 endometrial hyperplasia 55 antiangiogenic therapy 55 antitumor effect 55 polyps growths 55 thoracoscopic lobectomy 55 surgical excision 55 squamous histology 55 Metastatic breast cancer 55 estrogen receptor ER 54 malignant polyps 54 mutations 54 nutlin 3a 54 spinal metastases 54 Endometrial 54 cervical intraepithelial neoplasia 54 pre cancerous growths 54 HRCT 54 precancerous polyp 54 EGFR receptor 54 papillary thyroid carcinoma 54 pleura 54 HER2 overexpression 54 hypoechoic 54 uPA 54 cellularity 54 lymphocytic 54 mTOR inhibitors 54 GNAQ 54 bladder carcinoma 54 HCV infected 54 poorer prognosis 54 advanced neoplasia 54 colonic polyps 54 urothelial 54 progesterone receptor PR 54 neointimal 54 Sentinel node biopsy 54 relapsed SCLC 54 PKCi 54 trastuzumab 54 para aortic 54 oncogenes 54 HER2 54 tumor nodules 54 downregulated 54 SPINK1 54 Hepatocellular Carcinoma HCC 54 lateral ventricle 54 ERBB2 54 liver transplant recipients 54 HER2 negative 54 ectopic 54 BRCA1 mutation carriers 54 duodenal 54 E cadherin expression 54 pancreatectomy 54 BRCA mutation carriers 54 PrPSc 54 histologies 54 basal cell 54 zoledronic acid 54 uPAR 54 radiolabeled antibodies 54 PIK3CA 54 aplasia 54 chronic HBV infection 54 hypoplasia 54 colorectal metastases 54 colorectal polyp 54 normal karyotype 54 pancreatic ovarian 54 somatic mutations 54 colectomy 54 vimentin 54 mitral regurgitation 54 colorectal adenomas 54 intracranial tumors 54 myofibroblasts 54 Tavocept 54 associated lymphoid tissue 54 untreated metastatic melanoma 54 benign nodules 54 prostate carcinomas 54 draining lymph nodes 54 ocular melanoma 54 #F FDG PET 54 ipsilateral breast 54 squamous cell lung cancer 54 idiopathic myelofibrosis 54 rectal cancer 54 T1a 54 TOP2A 54 invasive carcinomas 54 hematopoietic 54 CD# + [001] 54 lung lesions 54 multicentric 54 tumor regrowth 54 ErbB2 positive 54 carotid stenosis 54 NF kB pathway 54 thyroid cancers 54 cytotoxic chemotherapy 54 NP CRNs 54 oesophageal 54 meningioma 54 FGFR3 54 squamous cells 54 testicular tumors 54 mesothelial cells 54 prostatic adenocarcinoma 54 transfected cells 54 xenografts 54 CGG repeats 54 lymphatics 54 CIN2 + 54 Fas ligand 54 Her2 54 gastrointestinal stromal tumor GIST 54 GIST 54 mutant protein 54 prognostic variables 54 amenorrhoea 54 hypercalcemia 54 HCCs 54 radiosensitive 54 gefitinib 54 embryonal rhabdomyosarcoma 54 TNF blocker therapy 54 PGE2 54 malperfusion 54 varicoceles 54 cytologically confirmed 54 Stat5 54 parathyroidectomy 54 fibroadenoma 54 adrenocortical cancer 54 evaluable patients 54 activated lymphocytes 54 prostate cancer metastases 54 melanoma lesions 54 necrotic core 54 STAT3 54 localized renal 54 vasculature 54 postoperative mortality 54 histologically confirmed 54 trabecular bone 54 allograft rejection 54 ErbB2 54 ductal adenocarcinoma 54 HER2 positive metastatic breast 54 mesenteric 54 sleeve lobectomy 54 tumor microenvironment 54 microcalcifications 54 myoblasts 54 Adenocarcinoma 54 CEACAM1 54 TGF beta signaling 54 prognostic significance 54 H pylori 54 gene polymorphisms 54 thymic carcinoma 54 posterior fossa 54 K#R [002] 54 progesterone receptor negative 54 NGAL 54 papillomas 54 DMARD 54 LHRH receptor positive 54 specific antigen PSA 54 hCG beta 54 NF2 54 invasive ductal carcinoma 54 endocrine therapy 54 cutaneous lesions 54 GBMs 54 miRs 54 primitive neuroectodermal tumor 54 invasive coronary angiography 54 toxicities 54 colorectal carcinomas 54 prostate pancreatic 54 aneuploidy 54 cancer mCRC 54 acute myelogenous leukemia AML 54 Candida infection 54 estrogen receptor beta 54 histopathologic 54 concurrent chemoradiation 54 myeloproliferative disorder 54 trophoblast cells 54 GSTP1 54 xenograft models 54 adenoid cystic carcinoma 54 ventricular myocardium 54 epithelial cells lining 54 KRAS mutations occur 54 medullary 54 estrogen receptor negative 54 Carcinoid tumors 54 Histologically 54 alveolar rhabdomyosarcoma 54 IL 1beta 54 antiangiogenic 54 fibroma 54 GSTM1 54 endobronchial 54 nonsmall cell lung cancer 54 metastatic gastric 54 androgen receptor AR 54 ccRCC 54 gene rearrangements 54 cancer metastasizes 54 Computed tomography 54 fine needle aspiration 54 bortezomib 53 molecular subtypes 53 CIN3 53 PGDH 53 hilar 53 fibrotic 53 brain lesions 53 Notch1 53 complete remissions 53 FOLFOX4 53 tumor necrosis 53 neuroblastoma tumors 53 hemorrhagic complications 53 pleural 53 ultrasonographic 53 EpCAM expression 53 intraoperative complications 53 mononuclear cells 53 advanced NSCLC 53 stenosis 53 inguinal 53 microalbuminuria 53 FGFR2 53 endothelial cell 53 phenotype 53 epithelial ovarian cancer 53 BRAF V#E mutation 53 colorectum 53 sporadic ALS 53 GRP# 53 varicocele 53 BRCA1 mutations 53 TP# mutations 53 lymph glands 53 lymphoid organs 53 precancerous polyps 53 proliferative diabetic retinopathy 53 hepatic fibrosis 53 cancerous tissues 53 lung nodule 53 radiation therapy 53 taxane therapy 53 hematopoietic cells 53 hyperoxaluria 53 localized prostate cancer 53 BRAF V#E 53 TGF alpha 53 neoadjuvant chemoradiotherapy 53 thymectomy 53 vertebral fractures 53 motor neuron degeneration